Introduction
============

Type 2 diabetes mellitus (T2DM) is a progressive disease, meaning that most patients will require the introduction of insulin into their treatment regimen at some point during the continuum of care [@b1]. To facilitate the transition to insulin, numerous clinical and real-world studies have investigated the efficacy and safety of initiating long-acting analogue insulins. In clinical studies, both insulin glargine (GLA; Lantus®, Sanofi US, Inc., Bridgewater, NJ, USA) and insulin detemir (DET; Levemir®, Novo Nordisk A/S, Bagsvaerd, Denmark) have been shown to result in equivalent improvements in glycaemic control with a low incidence of hypoglycaemia when used as part of a basal-bolus regimen [@b2]--[@b4]. Although glycaemic outcomes in such trials have been similar for these two basal analogue insulins, it has been noted that higher doses and twice-daily dosing are often required with DET compared with GLA [@b3],[@b4]. A recent trial has suggested that when both DET and GLA are used once daily as an adjunct to metformin, a greater proportion of patients treated with GLA reached glycated haemoglobin (HbA1c) levels \<7.0% than did patients treated with DET [@b5].

Attempts to examine the relative advantages of these insulin analogues in a real-world setting have proved difficult to interpret. Some studies have reported enhanced glycaemic control with GLA compared with DET, along with improved adherence and persistence, with no difference with regard to hypoglycaemia, healthcare costs or weight gain [@b6]--[@b8]; however, other studies found no difference in glycaemic control between the two insulin types [@b9],[@b11], with one suggesting that patients initiating DET were 30% less likely to gain 0.9 kg or more in body weight than GLA users [@b10]. Studies investigating the efficacy and safety of switching from GLA to DET are similarly conflicting in their findings. Although once-daily dosing of GLA and DET has been shown to result in equivalent 24-h glycaemic control, switching from GLA to DET was associated with improved HbA1c levels and fewer hypoglycaemic events, compared with remaining on GLA in an observational study of patients with type 1 diabetes mellitus (T1DM) and T2DM [@b7],[@b11],[@b12]. A retrospective analysis, however, reported that switching from GLA to DET did not improve glycaemic control among a cohort of patients with T2DM [@b13].

A recent longitudinal study sought to expand on these data by assessing real-world outcomes using a retrospective analysis of two large, independent, national, US databases comprising commercially insured and Medicare populations: the IMPACT® and Humana® cohorts [@b14]. The study found that, at 1-year follow-up, patients who had remained on GLA showed significantly higher persistence with and adherence to treatment compared with those who switched to DET (p *\<* 0.001). In addition, 37% of patients who switched to DET restarted GLA (p *\<* 0.05), compared with only 20% of GLA users returning to DET after having switched to GLA. Overall hypoglycaemia rates were significantly higher for patients continuing on GLA than for patients switching to DET in the Humana cohort (16 vs. 11%; p *\<* 0.05), but overall hypoglycaemia rates were similar in the IMPACT cohort (11 vs. 12%; p = 0.490).

In the present study, to further evaluate the consequences of insulin switching, we used data from patients\' medical records to investigate retrospectively the real-world clinical outcomes for patients with T2DM who switched between these two basal insulin analogues.

Methods
=======

The present analysis was a retrospective cohort study using the GE Centricity Electronic Medical Records (EMR) database from 1 July 2005 to 31 December 2012. In 2007, the GE Centricity EMR database contained the medical records of ∼30 million patients in 49 US states. As the analysis was performed on de-indentified data, approval from an ethics committee was not necessary.

Patients
--------

We analysed two cohorts in the present study: cohort 1 included patients who were previously treated with GLA and switched to DET (DET-S) or who remained on GLA (GLA-C); and cohort 2 included patients previously treated with DET and subsequently switched to GLA (GLA-S) or who remained on DET (DET-C). In cohort 1, the patients in the DET-S subgroup were required to have ≥1 physician prescription for GLA \<6 months before first DET physician prescription order date (after 1 January 2006). The first DET physician prescription date was designated as the index date. Patients in the GLA-C subgroup were required to have ≥2 GLA physician prescriptions starting from the third-quarter of 2005, without a subsequent physician prescription order of DET, with ≥1 of the orders being \<6 months before the index date. The index date was a randomly selected date between the second to the last GLA physician prescription. In cohort 2, patients in the GLA-S subgroup were required to have ≥1 physician prescription for DET \<6 months before the first GLA prescription order date (after 1 July 2006). The first GLA physician prescription date was designated as the index date. Patients in the DET-C subgroup were required to have ≥2 DET physician prescriptions starting from the first-quarter of 2006, without a subsequent physician prescription order for GLA. The index date was a randomly selected date between the second and last DET physician prescriptions dates.

Patients aged ≥18 years on the index date were included in the analysis if they had a diagnosis of T2DM \[International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes: 250.x0 or 250.x2\] with EMR activity data for ≥6 months pre-index (baseline) and 12 months post-index (follow-up). Patients were further required to have: ≥1 baseline HbA1c measure taken during the period 90 days before up to 15 days after the index date; ≥1 baseline body mass index (BMI) measure taken in the period 30 days before up to 15 days after the index date; and ≥1 follow-up HbA1c measure from the second-quarter until 3 months after the 1-year follow-up. In cohort 1, patients with baseline prescriptions for premixed insulin or basal insulins other than GLA \[i.e. neutral protamine Hagedorn (NPH) insulin, Lente, or Ultralente\] were excluded. Similarly, in cohort 2, patients with baseline prescriptions for premixed insulin or basal insulins other than DET (i.e. NPH insulin, Lente or Ultralente) were excluded.

Measures
--------

Baseline demographic and clinical characteristics included age, gender, region, race, geographic region, insurance type, BMI, weight, individual comorbidities and prescribed diabetes medications. In addition, the Charlson Comorbidity Index (CCI) score was calculated, which is the weighted sum of 19 categories of comorbidity defined using ICD-9-CM diagnoses codes, with a higher score indicating a more severe burden of comorbidity and a higher mortality risk [@b15],[@b16]. Clinical outcome variables were measured 1 year after the index date (follow-up) and included follow-up HbA1c, change in HbA1c from baseline, follow-up hypoglycaemic events, follow-up BMI, change in BMI from baseline follow-up body weight, change in body weight from baseline and follow-up oral antidiabetes drug (OAD) use (including GLA, DET and rapid-acting insulin). Baseline HbA1c measures were defined as those occurring between 90 days before and up to 15 days after the index date; baseline body weight and BMI measures were defined as ≥1 baseline measurement between 30 days before and up to 15 days after the index date. Follow-up HbA1c values were defined as those occurring during the period from the second-quarter until 3 months after 1-year follow-up, and follow-up body weight and BMI values were defined as those occurring during the 30 days before or after the end of the 1-year follow-up period (index date + 360 days). If patients had multiple HbA1c, body weight or BMI results during this period, the value dated closest to the index date was used as the baseline value, and the value dated closest to the end of the follow-up period was used as the follow-up value.

Hypoglycaemia was defined as a healthcare encounter (outpatient, inpatient or emergency department visit) with a primary or secondary ICD-9-CM diagnosis code for hypoglycaemia, based on the algorithm published by Ginde et al. [@b17]. Both the proportion of patients with ≥1 hypoglycaemic event (prevalence rate) and the average number of hypoglycaemic events per patient (event rate) during the baseline and 1-year follow-up period were identified.

Treatment persistence was defined as the patient remaining on the index long-acting insulin (GLA for GLA-C and DET for DET-S for cohort 1; DET for DET-C and GLA for GLA-S for cohort 2) during the 1-year follow-up period without discontinuation after study drug initiation. Based on the published methodology [@b18], study medication was considered discontinued if the prescription was not re-ordered by the physician within the expected time of medication coverage (the pre-defined 90th percentile of the time between first and second physician prescriptions among patients with ≥1 prescription). Patients who restarted their initial medication after a period of not having used this medication during follow-up were considered non-persistent. Persistence days were measured as the number of days between the index date and the discontinuation date. Sensitivity analyses were also conducted using 75th and 95th percentiles of the expected time of medication coverage.

Data Analysis
-------------

Descriptive and multivariate statistical methodologies were used to assess the baseline characteristics and to compare the outcomes over the 1-year follow-up period. To address potential selection bias in the real-world setting, in each cohort, patients from the two subgroups were matched by propensity-score matching, with a 1 up to 5 ratio in cohort 1 and a 1 up to 3 ratio in cohort 2, to balance baseline age, gender, race, geographic region, insurance type, physician specialty, index year, baseline comorbidity, baseline OAD use, concomitant medication, HbA1c and BMI. These ratios and matchings were chosen because our preliminary analysis revealed a prescription imbalance, with significantly more eligible patients in the GLA group when compared with the DET group, and a much lower number of patients in the 'switcher' groups versus the 'continuer' groups. Additionally, one-to-many matching has previously been validated as a method to increase precision in cohort studies, compared with one-to-one matching, and has also been supported in a recent review assessing the quality of statistical methodologies in matched case--control studies [@b19],[@b20]. Matching was implemented without replacement and any patient without ≥1 match was excluded from the analysis. Between-group covariate balance was evaluated using descriptive *t*-tests and chi-squared tests (with corresponding p-values) and standardized differences, where a standardized difference \<10 indicated adequate balance [@b21].

Because not every patient in the matched cohorts had follow-up BMI or body weight data, we conducted, as sensitivity analysis, ordinary least squares regressions for BMI and body weight changes, adjusting for potential baseline imbalances. The model used a larger set of covariates, which included patient demographics (age, gender, geographic locations and BMI categories), baseline comorbidities and some basic clinical characteristics (baseline OAD use, statins for baseline concomitant medication use, baseline HbA1c level and baseline hypoglycaemic events).

Results
=======

A total of 25 290 eligible patients were identified with 19 811 patients from cohort 1 (GLA-C, n = 17 783 and DET-S, n = 2028) and 5479 from cohort 2 (DET-C, n = 4431 and GLA-S, n = 1048). Patient attrition is shown in [Figure 1](#fig01){ref-type="fig"}. Significant baseline differences existed between the subgroups in each cohort (Table S1). In cohort 1, when compared with patients in the DET-S subgroup, patients in the GLA-C subgroup were older, were more likely to be black, were more likely to reside in the Midwest or West, were more likely to be enrolled in Medicare, had higher CCI scores and had lower HbA1c values. No significant differences were found for BMI or body weight between the GLA-C and DET-S subgroups at baseline. In cohort 2, when compared with the DET-C subgroup, patients in the GLA-S subgroup were younger, were more likely to be black, were more likely to reside in the Midwest or West, had higher HbA1c values, and had higher body weight and BMI values. Patients in the GLA-S and DET-C subgroups had similar CCI scores at baseline. For both cohorts, no significant differences were found for baseline hypoglycaemic events between groups.

![Patient attrition. BMI, body mass index; EMR, electronic medical records; HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus.](dom0017-0245-f1){#fig01}

After propensity-score matching, the final matched study population included 13 942 patients overall, with 10 657 from cohort 1 (GLA-C, n = 8860 and DET-S, n = 1797; female patients 54.7%, age 58.4 years, HbA1c level 8.7%, BMI 35.1 kg/cm^2^, weight 99.3 kg) and 3285 patients from cohort 2 (DET-C, n = 2427 and GLA-S, n = 858; female 53.5%, age 58.3 years, HbA1c level 8.8%, BMI 35.4 kg/cm^2^, weight 100.7 kg). The baseline demographic and clinical characteristics were balanced between treatment groups in each cohort (Table[1](#tbl1){ref-type="table"}).

###### 

Baseline characteristics among matched patients in cohorts 1 and 2

                                                                  Cohort 1      Cohort 2                                             
  --------------------------------------------------------------- ------------- ------------- -------- -------------- -------------- --------
  **Demographics**                                                                                                                   
   Women, n (%)                                                   996 (55.4)    4831 (54.5)   0.4848   477 (55.6)     1281 (52.8)    0.1556
   Mean (s.d.) age, years                                         58.1 (12.1)   58.4 (12.2)   0.2461   58.0 (12.5)    58.5 (11.9)    0.3701
   Race, n (%)                                                                                0.9760                                 0.9802
    White                                                         967 (53.8)    4840 (54.6)            490 (57.1)     1383 (57.0)    
    Black                                                         197 (11.0)    959 (10.8)             81 (9.4)       233 (9.6)      
    Hispanic                                                      63 (3.5)      297 (3.4)              21 (2.5)       62 (2.6)       
    Other                                                         47 (2.6)      222 (2.5)              23 (2.7)       56 (2.3)       
    Unknown/undetermined                                          523 (29.1)    2542 (28.7)            243 (28.3)     693 (28.6)     
   US region, n (%)                                                                           0.9293                                 0.9167
    Midwest                                                       414 (23.0)    1981 (22.4)            185 (21.6)     520 (21.4)     
    Northeast                                                     495 (27.5)    2441 (27.6)            196 (22.8)     571 (23.5)     
    South                                                         702 (39.1)    3502 (39.5)            383 (44.6)     1089 (44.9)    
    West                                                          186 (10.4)    936 (10.6)             94 (11.0)      247 (10.2)     
   Insurance type, n (%)                                                                      0.9650                                 0.7944
    Commercial                                                    391 (21.8)    1859 (21.0)            171 (19.9)     521 (21.5)     
    Medicaid                                                      51 (2.8)      254 (2.9)              12 (1.4)       38 (1.6)       
    Medicare                                                      636 (35.4)    3155 (35.6)            312 (36.4)     859 (35.4)     
    Self-pay                                                      31 (1.7)      150 (1.7)              23 (2.7)       53 (2.2)       
    Unknown                                                       688 (38.3)    3442 (38.8)            340 (39.6)     956 (39.4)     
  **Clinical characteristics**                                                                                                       
   Mean (s.d.) HbA1c, %                                           8.7 (1.9)     8.7 (1.9)     0.4172   8.8 (1.8)      8.8 (1.9)      0.6951
   HbA1c category, n (%)                                                                      0.0667                                 0.4926
    \<7.0%                                                        283 (15.7)    1561 (17.6)            127 (14.8)     333 (13.7)     
    ≥7.0 to \<8.0%                                                457 (25.4)    2398 (27.1)            215 (25.1)     658 (27.1)     
    ≥8.0 to \<9.0%                                                403 (22.4)    1826 (20.6)            196 (22.8)     547 (22.5)     
    ≥9.0 to \<10.0%                                               282 (15.7)    1272 (14.4)            141 (16.4)     354 (14.6)     
    ≥10.0%                                                        372 (20.7)    1803 (20.3)            179 (20.9)     535 (22.0)     
   Mean (s.d.) BMI, kg/m^2^                                       35.1 (8.2)    35.0 (7.9)    0.5837   35.6 (8.0)     35.4 (7.8)     0.5149
   Mean (s.d.) body weight, kg                                    99.5 (25.2)   99.3 (24.9)   0.7933   100.4 (24.8)   100.8 (25.1)   0.6780
   Mean (s.d.) CCI score                                          1.13 (1.49)   1.11 (1.49)   0.5523   1.02 (1.45)    1.01 (1.37)    0.8216
   Hypoglycaemia rates                                                                                                               
    Any hypoglycaemia, n (%)                                      24 (1.3)      92 (1.0)      0.2683   13 (1.5)       31 (1.3)       0.6024
    Mean (s.d.) number of hypoglycaemic events per patient year   0.02 (0.14)   0.01 (0.12)   0.3674   0.02 (0.14)    0.01 (0.13)    0.7201
   Comorbidities, n (%)                                                                                                              
    Hypertension                                                  1385 (77.1)   6807 (76.8)   0.8227   658 (76.7)     1884 (77.6)    0.5729
    Hyperlipidaemia                                               1429 (79.5)   7044 (79.5)   0.9862   697 (81.2)     1971 (81.2)    0.9876
    Neuropathy                                                    419 (23.3)    1959 (22.1)   0.2629   183 (21.3)     490 (20.2)     0.4773
    Nephropathy                                                   245 (13.6)    1096 (12.4)   0.1408   103 (12.0)     260 (10.7)     0.2995
    Retinopathy                                                   210 (11.7)    1020 (11.5)   0.8335   63 (7.3)       212 (8.7)      0.2056
    Mental illness                                                841 (46.8)    4061 (45.8)   0.4542   376 (43.8)     1086 (44.7)    0.6398
    Severe mental illness                                         183 (10.2)    918 (10.4)    0.8216   88 (10.3)      217 (8.9)      0.2538
   OAD use, n (%)                                                                                                                    
    Mean (s.d.) number of OADs                                    0.78 (0.92)   0.76 (0.91)   0.4920   0.89 (0.95)    0.85 (0.92)    0.3843
    Metformin                                                     627 (34.9)    3120 (35.2)   0.7938   347 (40.4)     981 (40.4)     0.9907
    Sulfonylurea                                                  377 (21.0)    1721 (19.4)   0.1306   192 (22.4)     546 (22.5)     0.9426
    Thiazolidinedione                                             233 (13.0)    1072 (12.1)   0.3068   114 (13.3)     276 (11.4)     0.1361
    Alpha-glucosidase                                             5 (0.3)       28 (0.3)      0.7927   3 (0.3)        5 (0.2)        0.4631
    Dipeptidyl peptidase-4 inhibitor                              127 (7.1)     661 (7.5)     0.5614   90 (10.5)      234 (9.6)      0.4740
    Meglitinide                                                   27 (1.5)      137 (1.5)     0.8907   15 (1.7)       33 (1.4)       0.4149
   Glucagon-like peptide-1 analogue use, n (%)                    90 (5.0)      454 (5.1)     0.8388   66 (7.7)       192 (7.9)      0.8378
   Regular insulin use, n (%)                                     51 (2.8)      229 (2.6)     0.5403   16 (1.9)       28 (1.2)       0.1194
   Rapid-acting insulin use, n (%)                                716 (39.8)    3553 (40.1)   0.8391   313 (36.5)     876 (36.1)     0.8396
  **Other**                                                                                                                          
   Physician specialty, n (%)                                                                 0.8747                                 0.9534
    Other                                                         66 (3.7)      334 (3.8)              75 (8.7)       199 (8.2)      
    Endocrinology                                                 136 (7.6)     624 (7.0)              51 (5.9)       139 (5.7)      
    Primary care                                                  1092 (60.8)   5388 (60.8)            496 (57.8)     1421 (58.5)    
    Unknown specialty                                             503 (28.0)    2514 (28.4)            236 (27.5)     668 (27.5)     

DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET; BMI, body mass index; CCI, Charlson Comorbidity Index; HbA1c, glycated haemoglobin; OAD, oral antidiabetes drug; s.d., standard deviation.

Insulin Utilization
-------------------

During 1-year follow-up, overall, switching from GLA to DET resulted in lower persistence with treatment, whereas switching from DET to GLA resulted in higher persistence. Among patients in cohort 1, those in the DET-S subgroup versus those in the GLA-C subgroup had significantly lower persistence with treatment (52.4 vs. 61.3%, respectively; p \< 0.0001) and significantly fewer treatment persistent days (311.6 vs. 331.0 days; p \< 0.0001). In cohort 2, however, the GLA-S and the DET-C subgroups had similar levels of treatment persistence (56.5 vs. 58.5%, respectively; p = 0.292) yet fewer treatment persistent days (320.7 vs. 325.3 days; p = 0.015).

Sensitivity analysis using 75th and 95th percentile of the time duration yielded similar results: 75th percentile: cohort 1 GLA-C versus DET-S subgroup, 21.2 versus 35.7% (p \< 0.0001); cohort 2 DET-C versus GLA-S subgroup, 24.7 versus 31.6% (p = 0.0001); 95th percentile: cohort 1 GLA-C versus DET-S subgroup, 63.1 versus 68.2% (p \< 0.0001); cohort 2 DET-C versus GLA-S subgroup, 67.0 versus 66.0% (p = 0.622).

In cohort 1, the use of rapid-acting insulin was significantly higher among the patients in the DET-S subgroup than among those in the GLA-C subgroup (57.6 vs. 52.5%; p \< 0.0001; [Figure 2](#fig02){ref-type="fig"}), and 26.9% of patients in the DET-S subgroup restarted GLA. In cohort 2, however, similar proportions of patients used rapid-acting insulin in the DET-C and GLA-S subgroups (50.4 vs. 51.1%; p = 0.712), and 18.6% of patients in the GLA-S subgroup restarted DET.

![Patients requiring rapid-acting insulin (RAI). DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET.](dom0017-0245-f2){#fig02}

Clinical Outcomes
-----------------

The baseline mean HbA1c level was similar between the treatment groups in each of the cohorts. In cohort 1, patients in the DET-S subgroup had a significantly higher follow-up HbA1c level ([Figure 3](#fig03){ref-type="fig"}A), a significantly lower HbA1c reduction ([Figure 3](#fig03){ref-type="fig"}B), and significantly lower proportions of patients achieved HbA1c \<7.0% ([Figure 3](#fig03){ref-type="fig"}C) and HbA1c \<8.0% ([Figure 3](#fig03){ref-type="fig"}D) at the end of 1-year follow-up compared with patients in the GLA-C subgroup. In cohort 2, however, compared with patients in the DET-C subgroup, patients in the GLA-S subgroup had a significantly lower follow-up HbA1c ([Figure 3](#fig03){ref-type="fig"}A) and a numerically higher (although not statistically significant) HbA1c reduction ([Figure 3](#fig03){ref-type="fig"}B), but there were no differences in the proportions of patients achieving an HbA1c level \<7.0% ([Figure 3](#fig03){ref-type="fig"}C) or \<8.0% ([Figure 3](#fig03){ref-type="fig"}D).

![(A) One-year follow-up glycated haemoglobin (HbA1c) values, (B) change in HbA1c from baseline, (C) proportion of patients achieving target HbA1c \<7.0%, and (D) proportion of patients achieving target HbA1c \<8.0%. DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET.](dom0017-0245-f3){#fig03}

For both prevalence and event rates of any hypoglycaemic events, no significant differences were found after follow-up between the DET-S and GLA-C subgroups in cohort 1 or between the GLA-S and DET-C subgroups in cohort 2 \[prevalence rate: 2.0 vs. 2.1%, p = 0.889; event rate (number of events/patient year): 0.023 vs. 0.026, p = 0.4424\] or between the GLA-C and DET-S subgroups in cohort 2 (2.3 vs. 1.6%, p = 0.2314; event rate: 0.028 vs. 0.021, p = 0.3727).

In both cohorts, baseline BMI and body weight were similar between the groups (Table[1](#tbl1){ref-type="table"}). In cohort 1, BMI at 1-year follow-up was 35.0 kg/m^2^ for both the DET-S and GLA-C subgroups (p = 0.843). There were also no significant differences in BMI change for patients in the DET-S and GLA-C subgroups after follow-up ([Figure 4](#fig04){ref-type="fig"}A). The 1-year follow-up weight was similar for the DET-S and GLA-C subgroups (99.3 vs. 99.4 kg; p = 0.881), with similar weight changes between patients in the DET-S subgroup and those in the GLA-C subgroup ([Figure 4](#fig04){ref-type="fig"}B).

![Changes in (A) body mass index (BMI) and (B) body weight at 1-year follow-up. DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET.](dom0017-0245-f4){#fig04}

In cohort 2, at the end of 1-year follow-up, patients in the GLA-S subgroup had a higher BMI (36.3 vs. 35.5 kg/m^2^; p = 0.052), but this was not statistically significant. Change in BMI was significantly different ([Figure 4](#fig04){ref-type="fig"}A). There were no significant differences at 1-year follow-up for body weight between patients in the GLA-S and DET-C subgroups (102.2 vs. 100.9 kg; p = 0.299); however, patients in the GLA-S subgroup had a greater change from baseline in body weight compared with those in the DET-C subgroup ([Figure 4](#fig04){ref-type="fig"}B).

Sensitivity analyses using ordinary least squares regressions yielded similar results: adjusted weight change: cohort 1 DET-S versus GLA-C subgroup, −0.18 versus +0.10 kg (p = 0.329); cohort 2 GLA-S versus DET-C subgroup, +1.48 versus +0.02 kg (p \< 0.001); adjusted BMI change: cohort 1 GLA-C versus DET-S subgroup, −0.18 versus −0.04 kg (p = 0.122); cohort 2 GLA-S versus DET-C subgroup, +0.48 versus − 0.05 kg (p \< 0.001).

Discussion
==========

The aim of the present study was to evaluate retrospectively the real-world clinical outcomes of switching between basal insulin analogues, compared with continuing on previous basal insulin, among patients with T2DM identified from the US GE Centricity EMR database. Overall, contrasting findings were observed when patients switched from GLA to DET, as compared with switching from DET to GLA.

In cohort 1, compared with patients in the DET-S subgroup, patients in the GLA-C subgroup had better clinical outcomes at 1-year follow-up, including lower HbA1c levels and significantly higher HbA1c reductions. In addition, significantly more patients in the GLA-C subgroup achieved the targeted HbA1c levels of \<7.0% or \<8.0% and those in the DET-S subgroup had significantly higher rapid-acting insulin use. In addition, no significant differences in hypoglycaemia rates and weight/BMI were observed between the two groups. These results could be attributable to lower persistence/adherence as patients might not be taking their full medication. In cohort 2, however, patients in the GLA-S subgroup had lower HbA1c levels and a numerically higher (but non-significant) HbA1c reduction; similar proportions of patients achieved HbA1c levels of \<7.0 or \<8.0%, and similar hypoglycaemia rates were seen in the two groups. Although 1-year follow-up body weight and BMI were similar, patients in the DET-C subgroup had a decreased BMI and a lower body weight increase, whereas patients in the GLA-S subgroup had increased BMI and significantly greater body weight increase. Although the patients in the GLA-S subgroup gained weight, the increase was \<1% which, it is suggested, is not clinically relevant [@b22], and may reflect differences in follow-up plasma glucose levels or other factors. Furthermore, the increase in weight with GLA could be taken to be a sign of better compliance. If a switch between insulin analogues is of a 'disruptive nature', it will result in decreased compliance. For example, if a regimen becomes more complex (from once daily to twice daily, adding a rapid-acting insulin etc.), it could lead to less of the typical weight gain associated with insulin treatment.

In cohort 1, the patients in the DET-S subgroup, who switched from GLA to DET, had lower persistence than those who remained on GLA (robust in sensitivity analyses). This could be attributable to the fact that most patients on DET administer twice daily, whereas most patients on GLA administer once daily [@b13],[@b23]. Unfortunately, this information is not captured in the GE Centricity EMR database. By contrast, in cohort 2, data on patients in the GLA-S subgroup switching from DET to GLA suggested similar overall persistence with treatment. Approximately 27% of the patients in the DET-S subgroup restarted GLA during the follow-up period. Of patients in the GLA-S subgroup, however, only 19% restarted DET during the follow-up period. Although the reasons for restarting the former insulin are not captured in the GE Centricity EMR database, these findings are consistent with a previous IMPACT and Humana database study [@b14]. Unlike randomized controlled trials, where patients are required to be 'persistent' with their therapy, real-world patients and physicians do not follow a stringent protocol and, therefore, any differences in patients\' persistence with their insulin treatment can translate into differences in clinical and economic outcomes [@b17].

Overall, contrasting outcomes were observed when patients were switched from GLA to DET, when compared with switching from DET to GLA. This raises questions about the therapeutic interchangeability of these two basal analogue insulins in clinical practice, although further studies are required to confirm this non-interchangeability. The results of the present GE Centricity EMR switching analysis, however, were highly consistent with the previously performed claims database analysis [@b14].

The present study has a number of strengths. The GE Centricity EMR database is a large and comprehensive source of data to understand clinical practice and outcomes in the real-world setting. This database contains rich clinical information, such as HbA1c level, weight and BMI, that is not available in insurance claim databases. Overall 25 000 patients were identified in this study, and almost 15 000 were propensity-score-matched and analysed, including those switching from DET to GLA and those switching from GLA to DET during the same time period. In previous observational studies on switching from GLA to DET [@b11],[@b13],[@b24], conflicting results were shown with relatively low numbers of patients included (30--1300 patients) and including either only patients with T1DM, or a mixed group of patients with T1DM and T2DM. Our previous study used administrative claims data [@b14], and the results described in the present study not only validate our previous findings with a different data source but also strengthen them with additional data on weight. One of the key limitations of the present study, however, is that the EMR analysis was carried out on primary care physician prescription data, rather than on claims databases. Prescription orders do not necessarily mean that the prescriptions were filled and taken as directed. In addition, certain data were not available, including glucose levels, the duration of treatment with the initial insulin, the duration of T2DM, and the reason for switching insulin (e.g. insurance required switching to other insulin). Although propensity-score matching was used to balance the baseline data between treatment groups, the differences between the groups were quite significant (Table S1) and the potential residual confounding might therefore still be present, particularly unobserved selection bias. In a real-world setting, switching patients to another treatment regimen may introduce confounding by indication, an important limitation to observational studies reporting on patients changing their treatment regimens, including the study described here. It is difficult to amend for this by analyses. Other potential sources of bias and confounding include the range of time from measurement of HbA1c to index date, differences in time for follow-up HbA1c and follow-up BMI, and patient/physician preference. In addition, the dose of insulin at the time of switching was not available in the GE Centricity EMR database and might have impacted on clinical outcomes, especially in patients who had recently switched insulin analogues and had not had the opportunity to titrate their dosage. Specifically, the present study was designed to compare between patients who switched to a different basal insulin and those who continued on the previous basal insulin. In the case of comparing patients in the DET-S with those in the GLA-C subgroup, patients in the latter subgroup may already be fully titrated, while it takes time for patients switching to DET to titrate. This may lead to an overestimation of the benefits of GLA compared with DET, representing a further limitation of this analysis. The same limitation applies to the comparison of the GLA-S with the DET-C subgroup. One approach to account for confounding by indication is to compare patients in the GLA-S subgroup with those in the DET-S subgroup directly; however, these patients had different baseline doses of basal insulin, and based on a real-world study among US patients initiating GLA or DET, it may be that higher insulin doses were used in the DET-treated patients [@b6]. It is not possible to establish causality from the differences in outcomes, nor are the data necessarily representative of all patients with T2DM. Patients could drop out for various reasons and thus selection may occur. In the present study, more patients treated with DET than those treated with GLA dropped out from the study population (56 vs. 35%) when 6-month baseline and 12-month follow-up were required. Similarly, only 8% of patients on DET treatment compared with 40% on GLA, dropped out when being aged \>18 years was required ([Figure 1](#fig01){ref-type="fig"}). Sufficient data on HbA1c levels and BMI were missing for half of the patients in this analysis, and this lack of completeness should be considered as a major limitation of EMR databases. When interpreting the findings of the present study, it should be remembered that, because of its limitations, the methodology used may have introduced bias or affected the 'real-world' representativeness of the results. Additionally, because of the real-world nature of the present study, patients did not have their HbA1c levels or BMI evaluated regularly and thus were excluded if they did not have baseline and/or follow-up HbA1c/BMI values. Overall, recognizing the inherent limitations of real-world data analyses, the findings of the present study alone should not be used to guide clinicians in the decision to switch insulin, but the findings do merit further investigation. Future studies should look more closely at a number of other factors, including the dose, duration of treatment, reasons for and cost-effectiveness of switching in patients with T2DM. In addition, although previous studies have suggested that in patients with T1DM DET was associated with a higher dose and more frequent twice-daily dosing than GLA [@b13],[@b24], large cohort comparative studies in patients with T1DM should be conducted to confirm these findings.

In conclusion, the results of the present study suggest that switching patients with T2DM from GLA to DET might lead to decreases in treatment persistence alongside having a negative effect on glycaemic outcomes. Maintaining patients on GLA or switching from DET to GLA, however, might be beneficial, although may result in minor weight gain. This suggests that the two basal insulin analogues might not be therapeutically interchangeable, and further studies are required to investigate this hypothesis.

This study was funded by Sanofi US, Inc. The authors received writing/editorial support in the preparation of this manuscript from Pim Dekker, PhD, of Excerpta Medica, funded by Sanofi US, Inc.

Conflict of Interest
====================

P. L. is a member of the advisory panel for Sanofi US, Inc. and Novo Nordisk, Inc., is a consultant for Novo Nordisk, Inc., Eli Lilly and Co. and Sanofi US, Inc., has received research support from Eli Lilly and Co., Sanofi US, Inc., Novo Nordisk, Inc., Amylin Pharmaceuticals, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc., and serves on speaker\'s bureaus for Eli Lilly and Co., Novo Nordisk, Inc., Amylin Pharmaceuticals, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. W. W., R. M., F. Y. and J. G. are employees of Sanofi US, Inc. L. X. and O. B. are employees of STATinMED, which received funding to carry out this work from Sanofi US, Inc.

P. L. co-developed the concept, interpreted the results of the analyses, reviewed manuscript outline and drafts and provided comments. W. W. proposed and co-developed the concept, co-developed the analysis plan, interpreted the results of the analyses, reviewed manuscript outline and drafts and provided comments. R. M. co-developed the concept, co-developed the analysis plan, interpreted the results of the analyses, reviewed manuscript outline and drafts and provided comments. F. Y. collected the data, co-developed the analysis plan, conducted statistical analyses and interpreted the results, reviewed manuscript outline and drafts and provided comments. L. X. collected the data, co-developed the analysis plan, conducted statistical analyses and interpreted the results, reviewed manuscript outline and drafts and provided comments. O. B. interpreted the results of the analyses, reviewed manuscript outline and drafts and provided comments. J. G. developed the concept, co-developed the analysis plan, interpreted the results of the analyses, reviewed manuscript outline and drafts and provided comments.

Supporting Information
======================

Additional Supporting Informationmay be found in the online version of this article:

###### 

Baseline characteristics among prematched patients of cohorts 1 and 2.
